UPPSALA, Sweden, Feb. 17, 2026 — Beactica Therapeutics AB, a Swedish precision medicine firm, today revealed that it, alongside prominent glioblastoma researchers at KU Leuven, has been awarded a EUR 2.5 million grant from the European Innovation Council (EIC). This funding is designated to progress a precision immune therapy for glioblastoma, which is the most prevalent and aggressive brain …